Pharmaceutical Research
Study examined plasma concentration of S18886 required for antiplatelet efficacy
Published in Heart Disease Weekly, September 4th, 2005
Scientists in France report, "We conducted a multicenter double-blind pharmacokinetic/pharmacodynamic (PK/PD) study of the new oral thromboxane receptor antagonist S18886 in 30 patients with peripheral artery disease who were randomized to receive five different oral dosages of S18886 (1, 2.5, 5, 10 or 30 mg) for 12 weeks (83 days). Our primary objective was to determine the effect of S18886 on platelet aggregation ex vivo."
P. Gaussem and colleagues of INSERM U428 in Paris reported, "Pharmacokinetics of S18886 was linear, with peak plasma levels being reached between 30...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Heart Disease Weekly
Source: Heart Disease Weekly (2005-09-04)
More Articles from Heart Disease Weekly
- Cardiac Transplantation
Caspase-3 inhibition prevents graft coronary artery disease in transplantation - Cardiac Transplantation
Changes in ejection fraction or volume in transplanted hearts are abnormal - Cardiology
Nifekalant renders electrical defibrillation more successful - Medical Devices
Technique may reduce morbidity of open-chest transmyocardial revascularization - Myocardial Infarction
Aqueous oxygen prevents LV remodeling, preserves LV ejection fraction - Ablation
Specially equipped electrodes may prevent burns during ablation - More from this issue of Heart Disease Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
